Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ARS Pharmaceuticals (SPRY) Operating Expenses: 2021-2024

Historic Operating Expenses for ARS Pharmaceuticals (SPRY) over the last 4 years, with Dec 2024 value amounting to $92.2 million.

  • ARS Pharmaceuticals' Operating Expenses rose 259.81% to $85.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $233.6 million, marking a year-over-year increase of 270.29%. This contributed to the annual value of $92.2 million for FY2024, which is 36.54% up from last year.
  • As of FY2024, ARS Pharmaceuticals' Operating Expenses stood at $92.2 million, which was up 36.54% from $67.5 million recorded in FY2023.
  • ARS Pharmaceuticals' 5-year Operating Expenses high stood at $92.2 million for FY2024, and its period low was $25.0 million during FY2021.
  • Moreover, its 3-year median value for Operating Expenses was $67.5 million (2023), whereas its average is $65.5 million.
  • Data for ARS Pharmaceuticals' Operating Expenses shows a peak YoY skyrocketed of 83.40% (in 2023) over the last 5 years.
  • ARS Pharmaceuticals' Operating Expenses (Yearly) stood at $25.0 million in 2021, then spiked by 47.56% to $36.8 million in 2022, then surged by 83.40% to $67.5 million in 2023, then skyrocketed by 36.54% to $92.2 million in 2024.